Sunitinib in metastatic renal cell carcinoma: Recommendations for management of noncardiovascular toxicities

Oncologist

Volumn 16, Issue 5, 2011, Pages 543-553

  Kollmannsberger, Christian ^a   Bjarnason, Georg ^b   Burnett, Patrick ^c   Creel, Patricia ^d   Davis, Mellar ^e   Dawson, Nancy ^f   Feldman, Darren ^g   George, Suzanne ^h   Hershman, Jerome ⁱ   Lechner, Thomas ^j   Potter, Amy ^h   Raymond, Eric ^k   Treister, Nathaniel ^l   Wood, Laura ^e   Wu, Shenhong ^m   Bukowskie, Ronald ^e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Pfizer Ltd   (United States)

^k BEAUJON HOSPITAL   (France)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Side effect management; Sunitinib; Toxicity; Treatment optimization

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; SUNITINIB;

ACRAL ERYTHEMA; ADVERSE DRUG REACTION; ANOREXIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEARTBURN; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; INDIGESTION; KIDNEY CARCINOMA; MEDICAL EXPERT; METASTASIS; MOUTH DISEASE; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORAL REHYDRATION THERAPY; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN TOXICITY; STOMATITIS; SURVIVAL; TASTE DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; VOMITING; XEROSTOMIA;

ASTHENIA; CARCINOMA, RENAL CELL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; EXANTHEMA; FATIGUE; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PYRROLES; STANDARD OF CARE;

EID: 79956269985     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0263     Document Type: Review

References (55)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
2. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
3. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
4. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-1043.
5. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-5608.
6. Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2009;66:357-371.
7. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-763.
8. CTEP NCI. Common Terminology Criteria for Adverse Events v3.0. May 22, 2003. Available at http://ctep.cancer.gov/reporting/ctc.html.
9. Rosen LS, Mulay M, Long J et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:abstract 765.
10. Maki RG, Fletcher JA, Heinrich MC et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2005;23:abstract 9011.
11. Atkinson BJ, Tannir NM, Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. American Society of Medical Oncology 2010 Genitourinary Cancers Symposium 2010;abstract 357.
12. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007;370:2071-2073.
13. Motzer RJ, Hudes GR, Curti BD et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007;25:3958-3964.
14. Yavuzsen T, Davis MP, Ranganathan VK et al. Cancer-related fatigue: central or peripheral? J Pain Symptom Manage 2009;38:587-596.
15. Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev 2001;81:1725-1789.
16. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81-83.
17. Minton O, Stone P, Richardson A et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008;CD006704.
18. Spence RR, Heesch KC, Brown WJ. Exercise and cancer rehabilitation: a systematic review. Cancer Treat Rev 2010;36:185-194.
19. Gramignano G, Lusso MR, Madeddu C et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 2006;22:136-145.
20. Sánchez-Barceló EJ, Mediavilla MD, Tan DX et al. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010;17:2070-2095.
21. Barton DL, Soori GS, Bauer BA et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010;18:179-187.
22. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664.
23. Wolter P, Dumez H, Schoffski P. Sunitinib and hypothyroidism. N Engl J Med 2007;356:1580.
24. Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351-355.
25. Grossmann M, Premaratne E, Desai J et al. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008;69:669-672.
26. Mannavola D, Coco P, Vannucchi G et al. Anovel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531-3534.
27. Wolter P, Stefan C, Decallonne B et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99:448-454.
28. Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011;117:534-544.
29. Baldazzi V, Tassi R, Lapini A et al. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2010; September 28 [E-pub ahead of print], doi: 10.1016;j.urolonc.2010.07.015.
30. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
31. Porta C, Paglino C, Imarisio I et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-134.
32. Beldner M, Jacobson M, Burges GE et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. The Oncologist 2007;12:1178-1182.
33. Suwattee P, Chow S, Berg BC et al. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 2008;144:123-125.
34. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961.
35. Yang CH, Lin WC, Chuang CK et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
36. Jacobi U, Waibler E, Schulze P et al. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1211.
37. Rouffiac V, Bouquet C, Lassau N et al. Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 2004;39:350-356.
38. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18: 338-340.
39. Tsai KY, Yang CH, Kuo TT et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006;24:5786-5788.
40. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
41. Sheen YS, Huang CL, Chu CY. Eccrine squamous syringometaplasia associated with sunitinib therapy. J Eur Acad Dermatol Venereol 2007;21: 1136-1137.
42. Thompson DS, Greco FA, Spigel DR et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial. Proc Am Soc Clin Oncol 2006;24: abstract 4594.
43. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007;32:71-74.
44. Botchkareva NV, Khlgatian M, Longley BJ et al. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 2001; 15:645-658.
45. Hemesath TJ, Price ER, Takemoto C et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998;391:298-301.
46. Mignogna MD, Fortuna G, Leuci S et al. Sunitinib adverse event: oral bullous and lichenoid mucositis. Ann Pharmacother 2009;43:546-547.
47. Taichman NS, Cruchley AT, Fletcher LM et al. Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest 1998;78:869-875.
48. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-2046.
49. Lordick F, Geinitz H, Theisen J et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006;64:1295-1298.
50. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003; 37:1276-1286.
51. Lee S, Chung H-C, Mainwaring P et al. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl 2009;7:428.
52. Lammie A, Drobnjak M, Gerald W et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-1425.
53. Mitchell SA, Beck SL, Hood LE et al. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11:99-113.
54. Muehlbauer PM, Thorpe D, Davis A et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapyand radiotherapy-induced diarrhea. Clin J Oncol Nurs 2009;13:336-341.
55. Adams LA, Shepard N, Caruso RA et al. Putting evidence into practice: evidence-based interventions to prevent and manage anorexia. Clin J Oncol Nurs 2009;13:95-102.